Appendix A: Proposal comment summary table

Respondent	Response	Details	Comment from Technology Appraisal
	to proposal		
Bristol Myer Squibb	Agree		BMS support a review of TA 70.
National Cancer Research Institute/Royal College of Physicians/Royal College of Radiologists/Joint Collegiate Council for Oncology/Association of Cancer Physicians	Disagree	"The drug is clearly benefiting at least 95% of patients (at least for a couple of years), and at least 60% of patients at 7 years. There are additional data since the 2003 review, though these are not necessarily entirely statistically watertight and may not give much additional information. Current studies are unlikely to produce additional information in this regard, as they compare with the second generation agents in newly diagnosed patients; 5 year data are unlikely for 4 years or so. With this in mind a review at this time may not be necessary."	Comment noted. The manufacturer has identified key evidence that would support a review of the guidance at this stage (see the response from Novartis below). Also the review will include the clinical and cost effectiveness of dose escalation, which is not covered by TA70.
Novartis	Agree	"Novartis fully support the decision to review TA70"	 There is new evidence available which can inform the review of TA 70: long term effectiveness Cytogenetic and molecular response rates Dose escalation
Royal College of Pathologists / British Committee for Standardisation in Haematology	No objection	"Royal College of Pathologists and the BCSH have no evidence that would suggest a change in the original guidance"	
Research Institute for the Care of Older People	No comment		
Royal College of Nursing	No objection		The RCN supports a review of TA 70.

No response received from:

Consultees	Consultees contd	Commentators (no right to submit or appeal) contd
Patient/carer groups		Possible comparator manufacturers contd
Afiya Trust	Professional groups	Alliance Pharmaceuticals (prednisolone)
African Caribbean Leukaemia Trust	British Association for Services to the Elderly	Amdipharm (prednisolone)

Consultees	Consultees contd	Commentators (no right to submit or appeal) contd
Age Concern England	British Geriatrics Society	Baxter Healthcare (cyclophosphamide)
 Anthony Nolan Bone Marrow Trust 	British Oncological Association	Cephalon (doxirubicin)
Black Health Agency	British Psychosocial Oncology Society	Eli Lilly and Company Ltd (vincristine sulphate)
CANCERactive	 British Society of Blood and Marrow 	GlaxoSmithKline (busulfan, mercaptopurine)
Cancer Black Care	Transplantation	Genus Pharmaceuticals (vincristine)
Cancer Equality	British Society for Haematology	Hospira UK (cytarabine, cyclophosphamide,
Cancer Voices	British Transplantation Society	dexamethasone, doxorubicin, etoposide and
Cancerbackup	Cancer Networks Pharmacists Forum	vincristine sulphate)
Chinese National Healthy Living Centre	Cancer Research UK	Medac UK (hydroxycarbamide, etoposide)
Chronic Myeloid Leukaemia Support Group	Royal College of General Practitioners	Merck Sharp and Dohme (dexamethasone)
 Confederation of Indian Organisations 	Royal Pharmaceutical Society	Napp Laboratories (cytarabine)
Counsel and Care	Royal Society of Medicine – Intellectual	Nordic Pharma (hydroxycarbamide)
Equalities National Council	Disabilities Forum	• Pfizer (cytarabine, doxorubicin, cyclophosphamide,
 Helen Rollason Heal Cancer Charity 	United Kingdom Clinical Pharmacy	idarubicin hydrochloride and prednisolone)
Help the Aged	Association	• Roche (IFN-α)
Leukaemia CARE	United Kingdom Oncology Nursing Society	Rosemount Pharmaceuticals (dexamethasone)
 Leukaemia Research Fund 		• Schering-Plough (dexamethasone and IFN-α)
 Leukaemia Society (UK) 	<u>Others</u>	Teva UK (etoposide)
Macmillan Cancer Support	Department of Health	Unichem (cytarabine, vincristine sulphate)
Maggie's Centres	Hampshire PCT	Waymade Healthcare (hydroxycarbamide,
Marie Curie Cancer Care	Warwickshire PCT Welch Accomply Covernment	mercaptopurine, (prednisolone)
Muslim Council of Great Britain	Welsh Assembly Government	Winthrop Pharmaceuticals UK (daunorubicin)
Muslim Health Network	Commentators (no right to submit or appeal)	Relevant research groups
National Cancer Alliance		Elimination of Leukaemia Fund
 National Council for Palliative Care 	General	 Institute of Cancer Research
 South Asian Health Foundation 	Age Concern Cymru	Leukaemia Busters
Specialised Healthcare Alliance	Board of Community Health Councils in	MRC Clinical Trials Unit
Sue Ryder Care	Wales	 National Institute for Health Research
Tenovus Cancer Information Centre	British National Formulary	 Policy Research Institute on Ageing and Ethnicity
	Cancer Care Cymru	 United Kingdom Clinical Research Network
	• Department of Health, Social Services and	 National Institute for Health Research Health
	Public Safety for Northern Ireland	Technology Assessment Programme
	Medicines and Healthcare products	
	Regulatory Agency	Associated Guideline Groups
	 National Association of Primary Care 	National Collaborating Centre for Cancer
	National Public Health Service for Wales	
	NHS Alliance	Associated Public Health Groups
	NHS Confederation	None
	 NHS Purchasing and Supply Agency 	

Consultees	Consultees contd	Commentators (no right to submit or appeal) contd
	NHS Quality Improvement ScotlandScottish Medicines Consortium	
	 <u>Possible comparator manufacturers</u> AAH Pharmaceuticals (cytarabine, dexamethasone and vincristine sulphate) 	